Movement disorders may be one of the important clinical manifestations of demyelinating disorders. They can manifest in Parkinsonism or a wide spectrum of hyperkinetic movement disorders including tremor, paroxysmal dyskinesia, dystonia, chorea, and ballism. Some of these disorders occur during an acute episode of demyelination, whereas others can develop later or even may precede the onset of the demyelinating disorders. The pathophysiology of movement disorders in demyelination is complex and the current evidence indicates a wide involvement of different brain networks and spinal cord. Treatment is mainly symptomatic and oral pharmacological agents are the mainstay of the management. Botulinum toxin and neurosurgical interventions may be required in selected patients.

**Keywords:** Corticosteroids, multiple sclerosis, NMOSD

**INTRODUCTION**

Movement disorders (MDs) may be one of the important clinical manifestations of demyelinating disorders. But the detailed description of different types of MDs has been rarely reported. Also, the dilemma of whether or not to include some features like spasticity, fasciculation, ataxia, tonic seizures, nystagmus, and saccades in MDs and reporting of new conditions like clumsy hand syndrome complicate the condition even more. The rarity of MDs in demyelinating disorders is surprising, considering that there is relatively frequent involvement of basal ganglia and subthalamic nucleus by multiple sclerosis (MS) plaques. Also, the persistence of MDs in some cases after remission of other symptoms by the corticosteroids are unsolved questions that lead to more aberrations. Further, most of the studies conducted in the past are on a small number of patients as case series and case reports. However, in the recent era, more knowledge of causal association and better management of the symptoms have led to a better understanding of the disease.

**Methods**

We reviewed English-written articles published in PubMed till 31st December 2021 using the combination of “Medical Subject Headings (MeSH)” (Multiple sclerosis OR Neuromyelitis Optica Spectrum Disorders (NMOSD)) OR anti-aquaporin-4 (AQP4) antibody OR Anti-myelin oligodendrocyte antibody disease (MOG-Ab disease) OR “Acute disseminated encephalomyelitis” OR “Osmotic demyelination syndrome” AND Movement disorders]. We retrieved 2415 articles, and after removing duplication and non-English articles, 199 articles were selected for the final review [Table 1]. Based on the review of literature, frequency [Table 2] and treatment [Table 3] of different MDs in different types of demyelinating disorders have been summarized.

**TREMOR**

Tremor is known to occur in MS from the very past. Joseph coats discussed tremor in his patient with disseminated sclerosis in 1879, but despite being one among Charcot’s triad (intention tremor, dysarthria, nystagmus), it was not much discussed. Prevalence of tremors in MS is variable, ranging from 58% to 77%. Tremor is moderate to severe in 15%, severe disabling in 3–15%, and may rarely be a presenting feature in only 0.3% of cases. Tremors most frequently occur in arms and hands with frequency ranging from 1–10 Hz, but may also be seen in the head, neck, vocal cords, trunk, and limbs. In most MS patients, tremor is postural and intentional; rest tremor is rare (1–3.33% cases only). Holmes, task-specific and orthostatic tremors have also been described in a few case studies. According to Pittcock, relapsing-remitting MS (RRMS) patients are more likely to have tremors compared to secondary progressive MS (SPMS). The localization of tremors in MS and other demyelinating lesions has been...
illustrated from the thalamus to the spinal level, which includes the basal ganglia, zona incerta, subthalamic nuclei, centromedian thalamic nuclei, cerebellum, cerebellothalamic connections in the pons, brain-stem, and spinocerebellar tracts in the spinal cord. Different authors have correlated the severity of tremors to various anatomic lesions. Boonstra et al. correlated tremor severity in MS with thalamic volume and superior cerebellar peduncle. Other studies have attributed it to pontine and cerebellar lesion load. The mechanism of tremor genesis in MS is not clear yet, and most hypotheses are made taking into account animal studies illustrating the dentate nucleus transmitting impulses to the thalamus via the superior cerebellar peduncle and red nucleus. Tremor is also modulated at the level of the muscle spindle and can be decreased by cooling, decreasing the sensitivity of the muscle spindle and thence peripheral nerve conduction, therefore, decreasing the input in the cerebellar circuits. A trial of stereotactic surgery in tremor ridden MS patients ascribed the ventralis-oralis-posterior (VOP) nucleus rather than the ventral intermediate nucleus (VIM) for causing the tremor, but this was not supported by other authors who attributed this to the edema and plaques induced disruption of the normal morphology of the brain leading to such aberration. The clinical improvement is being assessed by different scales, including accelerometry and polarized light goniometry in various studies.

| Search terms | Number of hits |
|--------------|----------------|
| Multiple sclerosis AND Movement disorders | 2268 |
| Neuromyelitis optica spectrum disorders AND Movement disorders | 66 |
| anti-aquaporin-4 (AQP4) antibody and movement disorders | 4 |
| Acute disseminated encephalomyelitis AND Movement disorders | 48 |
| Osmotic demyelination syndrome AND Movement disorders | 24 |
| Anti-myelin oligodendrocyte antibody disease AND Movement disorders | 5 |

| Movement disorders | Multiple sclerosis | Neuromyelitis optica spectrum disorders | Myelin oligodendrocyte glycoprotein (MOG) antibody disease | Acute disseminated encephalomyelitis | Osmotic demyelination syndrome |
|-------------------|--------------------|----------------------------------------|-------------------------------------------|---------------------------------|-------------------------------|
| Tremor            | +++                | +/−                                    | +                                         | −                              | +                             |
| Dystonia          | +                  | −                                      | −                                         | −/−                            | −                             |
| Paroxysmal dyskinesia | +                | +++                                   | −                                         | −                              | −                             |
| Myoclonus         | +                  | −                                      | −                                         | +/−                            | −                             |
| Myokymia          | +                  | −                                      | −                                         | −                              | +/−                           |
| Hemifacial spasm  | +/−                | −                                      | −                                         | −                              | −                             |
| Tics              | +                  | −                                      | −                                         | −                              | −                             |
| Chorea            | +                  | −                                      | −                                         | −                              | −                             |
| Restless leg syndrome | +                  | −                                      | −                                         | −                              | −                             |
| Parkinsonism      | +                  | −                                      | −                                         | −                              | +++                           |
| Ocular manifestations | +                | −                                      | −                                         | −                              | −                             |

+ : Occasional; ++ : Frequent; +++ : Very frequent; − : Absent; +/− : Lack of evidence

| Movement disorders | Corticosteroids | Isoniazid | Anti-epileptic drugs | Tetrahydrocannabinol | Botulinum toxin | Levodopa | Thalamo-tomy | DBS/Thalamic stimulation |
|--------------------|----------------|-----------|----------------------|----------------------|----------------|----------|--------------|--------------------------|
| Tremor             | +              | ++        | +                    | +                    | /−            | +/−      | ++           | +++                      |
| Dystonia           | +              | +         | +                    | +                    | +/−           | −        | −            | +                        |
| PD                 | +              | +         | +                    | +                    | +/−           | −        | −            | +                        |
| Myoclonus          | +/−            | +         | +/−                  | +/−                  | −             | +/−      | −            | +                        |
| Myokymia           | +/−            | +         | +/−                  | +/−                  | −             | +/−      | −            | +                        |
| HFS                | +              |          | +                    | +                    | +/−           | −        | −            | +                        |
| Tics               | +              |          | +/−                  | +/−                  | −             | +/−      | −            | +                        |
| Chorea             | +              |          | −                    | −                    | −             | +/−      | −            | +                        |
| RLS                | +              |          | −                    | −                    | −             | +/−      | −            | +                        |
| Parkinsonism       | +/−            |          | +/−                  | +/−                  | −             | +/−      | −            | +                        |
| Ocular manifestations | +/−    |          | +/−                  | +/−                  | −             | +/−      | −            | +                        |

+ : Mild benefit; ++ : Moderate benefit; +++ : Significant benefit; − : No benefit; +/− : No clear evidence of efficacy
A tremor in MS is one of the most difficult symptoms to treat and imposes significant functional disability. Various medications, including isoniazid, topiramate, benzodiazepines, beta-blockers, ethanol, antiepileptics, mood stabilizers, leviteracetam, antispasmodics, and dementia medications, have been tried to produce an effect on the magnitude of action tremor.\cite{23,27-30} Overall, among these, isoniazid is the most evaluated and shown to provide improvement in 60–80% of cases.\cite{27} According to the The North American Research Committee on Multiple Sclerosis (NARCOMS) trial in 2016, moderate to severe tremor is more likely to respond to the medications acting via the Gamma-aminobutyric acid (GABA)ergic pathway compared to mild and disabling tremor.\cite{25} In the late ’90s, various drugs from oral cannabis, nabiximol spray, phenobarbital, topiramate, and glutathione to intrathecal baclofen were used, some of which showed improved by their sedative, anticonvulsant, and anticholinergic effect, but due to their nonspecific nature and side-effects, the American Academy of Neurology guidelines are against their use.\cite{31,32} Vagus nerve stimulation has also been tried successfully in postural cerebellar tremors with dysphagia in MS patients. Few trials available showed up to 67% improvement over three months.\cite{33,34} The unilateral thalamotomy of VIM or VOP is considered the treatment of choice and has shown to be effective in postural tremors (50%) and intention tremors (72%). The response remains for more than one to five years. Due to higher chances of complications like subdural hematoma and intracerebral hemorrhage with thalamotomy, and the comparatively reversible nature of complications with thalamic deep brain stimulation (DBS), the latter is considered the preferable approach.\cite{7,20,35,56} The mean improvement with DBS is reported to be 39% which can be a maximum of up to 100%.\cite{37,38} But due to the fluctuating/progressing nature of the disease in MS, unlike steady deterioration in Parkinson’s disease, the regression in improvement cannot be precisely expected.\cite{37}

Due to different disease courses and tremor characteristics, the stimulation site varies in MS compared to other causes of tremor.\cite{33,34,38} VOP/VIM for distal single frequency tremor and VOP and Zona inserta (ZI) for mixed proximal and distal joint tremor with broader frequency are generally considered.\cite{40} Postoperative complications like epilepsy, sensory disturbances, hemiparesis, aphasia, dysphagia, transient bladder disturbances, depression, confusion, lethargy, and somnolence were also reported.\cite{9,41-44} Magnetic resonance-guided focussed ultrasound has also been used for unilateral tremors in MS patients.\cite{45} Keeping all the contraindications in the concern like weakness of the tremulous extremity, psychiatric comorbidity, and other neurosurgical contraindications, DBS is effective for bilateral tremors.\cite{46} Besides this, upcoming technologies like exoskeleton may be another treatment option for tremor management in patients with MS, but they are still in the rootlet stage.\cite{47}

**Paroxysmal Dyskinesia**

Paroxysmal dyskinesia (PD) remained hidden under the cloak of epilepsy (reflex) owing to its paroxysmal nature and the responsiveness to the anti-epileptic drugs and had not got a separate name until the 1940s when Mount and Reback used the term “paroxysmal choreoathetosis” instead of epilepsy due to a lack of consciousness.\cite{48} PD was further classified by Kertesz into kinesogenic (PKD) and non-kinesogenic (PNKD), and later, three more variants evolved based on relation to sleep, exercise, and childhood dystonic form, i.e., paroxysmal hypnagogic choreoathetosis (PHC), paroxysmal exercise-induced dyskinesia (PED), and paroxysmal dystonic choreoathetosis (PDC).\cite{48-52} But confusion persisted about the paroxysmal dystonia, and tonic spasm/tonic seizure. Later, tonic seizure (TS), and paroxysmal dystonia were established under “other episodic disorders that can be confused with a paroxysmal MD” separating it from PD.\cite{49,53} However, in MS, the three forms mostly discussed are PKD, PNKD, and PED (paroxysmal exertion induced dystonia). PKD is a major form of primary origin, and secondary PKD (structural and other recognizable causes) accounts for 7.6% of cases only.\cite{54} Primary and secondary PKD have also been differentiated based on the duration of each episode in which the primary lasts for <5 minutes (usually 30–90 seconds) and the secondary PD lasts longer (>5 minutes). However, some authors are not much supportive of this statement.\cite{54,55}

The tonic seizure is the second most common MD reported in MS.\cite{50} It was initially described by the Gullian in NMOSD but later illustrated by Mathews in MS, as abrupt onset transient painful extensor or flexor spasm in one or more limbs with or without trunk or face or lingual involvement of brief duration with frequency up to 200 per day.\cite{50,56,61} The incidence is found at 3.8% to 17% in MS and often presents as an initial symptom.\cite{58,62-65} In some studies, autonomic symptoms like ipsilateral sweating have also been reported.\cite{50,58,66} Isometric, complex, and adductor/inversion TS have also been described in NMOSD.\cite{5,67-69} Hyperventilation is the most common trigger, followed by spinal flexion, sudden exertion, sexual intercourse, anxiety, fatigue, ingestion of alcohol, exposure to noises, and moving into a cold environment.\cite{55,70-72} The lesion can be localized anywhere in the motor pathway from the spinal cord (cervical cord), brain-stem, cerebral peduncle, thalamus, posterior limb of the internal capsule, and corpus callosum. But the spinal cord is likely to be the most common, where the motor and sensory fibers are situated close to each other.\cite{55,73,74}

As the knowledge evolved, it seems that not the lesion per se causes the spasm, as the TS was found to be present even before the appearance of spinal cord lesion (Cervical and brain-stem >dorsal) on magnetic resonance imaging (MRI) and sometimes may appear during the treatment phase also, when other symptoms start disappearing.\cite{75,76}

Being more associated with a spinal lesion, it is not surprising that TSs are more commonly found in NMOSD (3–98%), which is also more associated with Longitudinal extensive transverse myelitis (LETM) than MS.\cite{76,77} Kim et al.\cite{75} depicted the sensitivity and specificity of myelitis for TS as 80% and 63.3%, respectively, in NMOSD, and has no association with the length and location of the spinal cord lesion. Besides

---

**References**

1. Singh S, Pandey SK. Movement Disorder in Demyelinating Disease. Ann Indian Acad Neurol 2022;25(5):821-832.
this, it can also be found in the thalamic/pons/capsular lesion in MS patients.\[73,76\] TS has a localizing and predictive value also in suspected cases of transverse myelitis with NMOSD.\[59,79,80\] Few cases of TS have been described in Acute disseminated encephalomyelitis (ADEM) as well.\[81\] In one comparative study, the association of TS was found to be higher for NMOSD than Myelin oligodendrocyte glycoprotein (MOG) antibody disease, which can be obvious by the fact that MOG-Ab disease is associated with more of the caudal (conus) spinal cord, whereas TS is found to be more in the cervical spinal cord.\[82\] Various case series and case reports have shown the association between the two, and sometimes, TS may present as an initial symptom.\[61-63,70\]

TS is managed by anticonvulsant drugs like carbamazepine, phenytoin, valproate, primidone, phenobarbitone, levetiracetam, clonazepam, gabapentin, and in refractory cases, topiramate, lidocaine, mexetine, and tiagabine, acetazolamide, cannabis, and botulinum toxin have also been tried successfully.\[10,82-87\]

HEMIDYSTONIA

Several cases of hemi-dystonia secondary to the lesions in the caudate, lentiform nucleus, thalamus, and subthalamus were commonly reported in MS, but most of them had paroxysmal symptoms.\[74,88\] A few cases of sustained hemi-dystonia have also been reported, but the causative lesion has not been found.\[88,89\]

PHARYNGEAL TONIC SPASM

Like other dystonia in MS, pharyngeal tonic spasm also is a rare entity, and two cases have been reported proven by electromyography, which illustrated the hypertonic activity of the cricopharyngeal muscle; however, no anatomical lesion was described.\[90,91\]

SPASMODIC TORTICOLLIS

Spasmodic torticollis (ST) has been rarely reported with demyelinating lesions. A case report has been traced back to Guillian, who first reported ST in a patient with an 11-year history of having MS.\[92\] Later other studies also linked ST with MS lesions involving basal ganglia, periventricular to subcortical regions, cerebral peduncle, ponto-mesencephalic junction, cerebellum, and upper cervical spinal cord.\[55,92-96\] One case of painless torticollis has also been reported in ADEM patients.\[96\] Unlike PD, no specific correlation or causal mechanism (except anti-basal ganglia antibody) has been illustrated and has long been considered a coincidental finding.\[97\]

Cases of MS with initial presentation as torticollis has been reported, implying the need for MRI and other evaluation studies in patients with focal dystonia.\[93\] There are case reports of ST precipitating with exacerbation of MS and recovering on its own. Some of these patients got remitted with steroids, and in others, botulinum toxin was the only rescuer.\[98\] One study demonstrated the resolution of symptoms with ACTH.\[99\]

CATATONIA

Catatonia is characterized by catalepsy, that is, maintaining abnormal posture for a prolonged duration, waxy flexibility (retention of the limbs for an indefinite period), mutism, negativism, and bizarre behavior.\[99-102\] In MS patients with catatonia, MRI findings have documented demyelinating lesions in frontal, supplemental motor areas, basal ganglia, and amygdala.\[101\]

MYOCOLONUS

In MS, the most commonly reported myoclonus is the palatal myoclonus.\[103-105\] One case of propriospinal myoclonus has also been described by Kapoor et al., and a few cases of branchial/spinal myoclonus due to demyelinating lesion have been described by Jankovic in his study of the spinal myoclonus.\[106,107\] Foschi et al.,\[107\] in their review article, purred about the existence of propriospinal myoclonus in sleep due to intramedullary demyelinating plaque, but no case has been reported. There are case reports of spinal myoclonus in ADEM and opsoclonus myoclonus syndrome in MOG-Ab disease.\[108,109\] It has been postulated that the myoclonus in demyelinating disorders is likely to be due to a loss of inhibition from the suprasegmental pathway or the overactivity of the anterior horn cell with hyper-excitability of the demyelinated axons.\[104,105,110\]

There is no definitive treatment for myoclonus in demyelinating disorders. Various drugs, including carbamazepine, primidone, clonazepam, tizanidine, levetiracetam, baclofen, cannabis, and dimethyl fumarate, have been tried with no significant benefit.\[32,111-114\]

MYOKYMIA

Buzzard first described it as “fibrillotonic facial spasm”. Later, Bernhardt (1902) coined the term “Facial Myokymia” and Oppenheim (1916) proposed its association with MS.\[115\] Myokymia has been classified based on the region involved, i.e., focal and generalized. The focal myokymia is primarily localized to the facial region, and generalized is used interchangeably with limb myokymia. Continuous facial myokymia (eyelid myokymia) is more commonly seen in MS as compared to limb myokymia.\[115,116\] Facial myokymia is more likely to be associated with demyelinating lesions in MS localizing to the post-genu position of the facial nerve in the dorsolateral pontine tegmentum.\[117\] Recognizing this phenomenon is of clinical significance in making the diagnosis of MS, as facial myokymia due to MS is usually transient, lasting from two weeks to six months.\[117\] On Electromyography (EMG), it presents as short bursts of ectopically generated motor neuron unit potentials firing at a frequency of 2–10 Hz in a rhythmic or semi-rhythmic fashion. The differential diagnosis of EMG includes synkinesis, fasciculation (giant voltage, simple, solitary action potential, firing at random), post-paralytic facial spasm (burst at irregular interval, increased intensity following voluntary facial contraction), cryptogenic
facial spasm (irregular in rhythm, region, and degree), facial jacksonian epilepsy or epilepsy partialis continua (absence of wavy character and clonic type spasm of brief duration), blepharospasm, neuromyotonia, myotonic discharges, and complex repetitive discharges. Radu and Jacob, in their respective studies, tried to prove the correlation between myokymia and the demyelinating lesion. The MRI lesion emergence and evanescence with myokymia were used as evidence to prove the simultaneity. Similarly, Kojima also presented a case of MS with initial presentation as facial myokymia with the lesion in the lateral tegmentum pontine plaque/infranuclear area of the facial nerve. In comparison to MS, the lesion is infranuclear, and it is the deafferentation of the nerve that leads to myokymia in Guillain-Barré syndrome (GBS). Cases that initially present with facial myokymia due to MS are usually self-limited. If methylprednisolone and carbamazepine are not effective, botulinum toxin can be tried. Besides MS only a few case reports have been reported regarding the presence of eyelid myokymia in other demyelinating disorders like ADEM. Spastic pertic hemifacial contracture (SPHC) is the sustained contraction of the ipsilateral facial muscles with facial paresis, which differentiates it from myokymia. SPHC is also caused by the pontine (dorsolateral) lesions and recovers spontaneously. EMG findings are suggestive of low amplitude, incomplete interference, and impaired recruitment pattern during voluntary contraction. To date, only nine cases have been reported, and two were associated with MS. The underlying mechanism was postulated as hyperexcitability of the facial neurons due to the absence of inhibitory action of the corticobulbar fibers. Patients were treated with gabapentin, baclofen, and carbamazepine.

Hemifacial Spasm

Hemifacial spasm (HFS) is a short, continuous, spontaneous paroxysmal contraction of facial muscles supplied by the facial nerve, caused by the kindling effect where the damaged root entry zone acts as a trigger, generating the impulses and transmitting them both anti and orthodromically. The antidromic impulses activating the facial motor nucleus send the impulses down the facial nerve, thereby generating the HFS. An alternate theory has also been proposed of ephaptic transmission and malfunction with rearrangement of facial nucleus, respectively. The association with trigeminal neuralgia has also been suggested, but researchers have not found much evidence. Besides typical anticonvulsive drugs, baclofen, botulinum toxin, microvascular decompression, and other surgical approaches have been used.

Choreo-Athetosis

Only a few cases of chorea and ballism in MS have been discussed so far. Management available varies, as in some cases, it improves with typical drugs (like chorea due to other causes). Proving the causal association between the two, some cases showed improvement with anti-inflammatory drugs and recovery with resolution of the lesion. However, few cases did not suggest coincidence. DBS has also been tried with successful results in a few studies.

Tics

Tics in demyelinating disorder are unheard entity, and only a few cases so far have been described with controversy regarding their coexistence as a causal association or incidental finding. Tics are more specific to the RRMS rather than SPMS. It occurs due to disinhibition of the frontal subcortical thalamocortical circuitry controlling voluntary movement. Other than that, lesions of the cortices and corpus callosum and thinning of sensorimotor areas (a ventral portion of the homunculus) have also been found. Various treatments, including clonidine, antipsychotics, and botulinum toxin, have been tried in motor tics with dystonic features. As there is a male preponderance (male: female; 4:1), androgen receptor blocker flutamide has also been tried in placebo-controlled cross-over trials. The use of cannabis is also reported but controversial.

Restless Legs Syndrome

Restless leg syndrome (RLS) usually occurs in MS patient with a long evolution time and should be differentiated from pseudo-RLS [Table 4]. The frequency of RLS is found to be more in patients with MS (RRMS > PPMS) than without it. No association with age has been established. RLS in MS is also associated with the prognosis, the quality of life,

| Table 4: Differences between restless legs syndrome and pseudo-restless legs syndrome |
|---------------------------------------------|-------------------------------------------------|-----------------------|
| Clinical features                          | Restless legs syndrome (RLS)                     | Pseudo-RLS            |
| Major symptoms                             | Neurosensory disorder, characterised by discomforting leg sensations like dys/paraesthesia and pain. | Dysesthesia, paresthesia, and spasticity in limbs mimicking RLS. |
| Relationship with sleep                    | Classically appearing at night before going to sleep | Worst when subjects wake up |
| Urge                                       | Causes the urge to move                          | Do not cause the urge to move |
| Frequency                                  | Dysesthesia is more or less intermittent         | Dysesthesia is relatively constant |
| Relationship with leg-movement              | The decrease in moving the affected limb         | Do not decrease on moving the limb |
| Site                                       | Usually occur in the calf region and aggravate to thighs and lower leg | Characterized by ankle involvement |
| Association with periodic leg movement syndrome | Present                                               | No such association present |
and cognitive impairment (affecting the quality of sleep), as subjects with RLS are found to have a higher disability and risk of depression than subjects without RLS. For the assessment of severity, the International Restless Legs Syndrome Study Group (IRLSSG) criteria has been used.\textsuperscript{145,146}

There is not much difference in the management of RLS in patients with MS, and iron, dopamine agonist, and anti-epileptic drugs are the mainstay of the treatment.\textsuperscript{146}

**Parkinsonism**

Parkinsonism in MS is mostly due to lesions of the substantia nigra, and thalamus. However, other lesions in the midbrain, frontal lobe, and globus pallidus have also been illustrated in a few studies, but the significance of these findings has not been proven yet.\textsuperscript{136,147-150} The parkinsonism associated with MS is usually bilateral with rapid onset, much milder, and usually in the younger population.\textsuperscript{151} In a case series of MS patients, the parkinsonian symptoms completely resolved with intravenous methylprednisolone with minimal/no response to other typical antiparkinson drugs like levodopa/carbidopa and ropinirole.\textsuperscript{148,151-154} On the other hand, in another case series of MDs in RRMS, Nociti et al.\textsuperscript{136} illustrated two cases of mild parkinsonism who did not respond at all to corticosteroids and improved with levodopa/carbidopa. A similar illustration is given by others, hypothesizing that parkinsonism may be caused by MS lesions in basal ganglia and subside by corticosteroids like other symptoms suggesting an association between the two.\textsuperscript{155,156} However, some studies fail to show improvement with both corticosteroids and levodopa.\textsuperscript{157} Two cases of atypical parkinsonism (Multiple system atrophy) in MS have been reported with lesions in the midbrain, inferior olive, and cerebellum. The patients deteriorated on levodopa/carbidopa, and the autopsy proved the demyelinating pathology.\textsuperscript{157-159} Besides antiparkinsonian drugs and corticosteroids, other modalities, including electromagnetic field, have also been tried successfully and shown good response.\textsuperscript{159}

**Eye Movement Disorder**

Eye MD was illustrated to be present in MS (36-84%) from the beginning, but their diagnostic value has always been a big question mark,\textsuperscript{160} as even after several studies, their true value was never proven till 1986.\textsuperscript{161} Besides, it also plays a role in maintaining the quality of life, as the patient having the same found to have poorer quality of life.\textsuperscript{161} How oculomotor disturbances are different from other MDs in MS is that unlike other MDs commonly presenting in the RRMS subtype, these are assailant to progressive subtypes (90-95% cases, throughout the course of MS).\textsuperscript{162} Various ocular abnormal movements can appear in MS, with internuclear ophthalmoplegia (INO) being the most frequent, constructing 30% of all MS cases.\textsuperscript{162-165} As INO progresses, saccadic latency, velocity, and range of motion are also affected progressively, leading to visual confusion, oscillospia, reading fatigue, diplopia, and loss of stereopsis.\textsuperscript{166,167} One case of ocular flutter has also been reported in MOG-Ab disease.\textsuperscript{168}

**Saccades**

Saccadic dysmetria is the most common eye MD seen in chronic MS and clinically isolated syndrome (CIS), commonly occurring secondary to the lesion of the dorsal vermis.\textsuperscript{169} Saccades have three important components, each of which localizes the lesion at a different level, i.e., peak saccadic velocity (PSV) denotes the function of the paramedian pontine reticular formation (PPRF), saccadic accuracy is a function of the cerebellum, and basal ganglia and latency depict the neural conduction times of the whole visual (afferent and efferent) pathway system.\textsuperscript{170} The role of this parameter is in the early detection of MS.\textsuperscript{170} Hypometria occurs in a lesion of the vermis alone, whereas hypermetria occurs due to the involvement of the deep nuclei.\textsuperscript{171} There can be an increase in saccadic latency, initiation time, average inter-saccadic interval, and decreased saccadic velocity, which is studied as a marker of cognitive slowing (hypometric saccades).\textsuperscript{171} Decreased saccadic latency seen in CIS cases is probably due to reduced inhibition.\textsuperscript{172} To standardize the disturbance, the vertical direction accuracy index (VDI) has been used, which accounts for all the components of the saccades like velocity, acceleration, amplitude, and latency in both the abducting and adducting eye.\textsuperscript{173} In a study of nine patients with INO, it was illustrated that VDI increased in mild cases of INO; however, in severe cases, it decreased.\textsuperscript{173} Last is the phase-plane analysis which takes the velocity as a function of eye position and removes the variations caused by the temporal variation.\textsuperscript{174} Besides this, nystagmography was also used in some studies for illustrating the slowing of saccades.\textsuperscript{174,175} However, these parameters act as indicators but cannot be fully relied on.\textsuperscript{175}

Saccades can be measured by infrared reflection oculography, infrared oculography, infrared eye-tracker, electro-oculographic technique, and the combination of infrared oculography and diffusion tensor imaging (DTI).\textsuperscript{175} Various medications have been tried to improve the latency of saccades, including fampridine.\textsuperscript{176}

**Pursuit**

Pursuit is the smooth tracking movement that helps in keeping the targeted object fixated at the fovea. It originates from cortical and subcortical areas, including the frontal eye field, dorsolateral pontine nucleus, cerebellar flocculus, vestibular nuclei, and dorsal vermis. Impaired pursuit is not uncommon in MS, and it has been illustrated as a marker of CIS in many studies. It can be seen in 30% of MS cases, leading to a low-gain pursuit in which the eye movements are inordinately slower than the moving target.\textsuperscript{177,178} Due to the involvement of cerebellar flocculus, the vestibular-ocular reflex cancellation is impaired, which is imperative for the foveal fixation of the target during the active head and eye movement.\textsuperscript{179}

**Nystagmus**

Nystagmus is an oscillatory movement of the eye and occurs in 70% of MS patients affecting tracts from the cerebellum, dorsal medullary, medial pontine, and superior colliculi, leading to
Singh and Pandey: Movement Disorder in Demyelinating Disease

alteration of the fixation, gaze holding, vestibular-ocular reflex, and thence to nystagmus.\textsuperscript{[180]} However, it is not as common in chronic MS as other oculomotor dysfunction.\textsuperscript{[180]} Nystagmus is hypothesized to be due to the alteration in the neural integration system. This visual stimulus also impacts eye movement, as a greater oscillation of nystagmus has been found in the eye with optic nerve involvement.\textsuperscript{[181]}

MS is the most common cause of acquired pendular nystagmus (APN) secondary to the lesions of the paramedian tract.\textsuperscript{[182–184]} Optokinetic nystagmus has also been reported in MS.\textsuperscript{[185]} Treatment suggested is gabapentin, memantine, 3,4-diaminopyridine, baclofen, fampridine, prisms, and surgery. Besides these, the vibratory method has also been tried. Beh et al.\textsuperscript{[186]} used a mini muscle massager over the vertex, mastoid, and chin in patients of MS with monocular horizontal nystagmus and vexatious oscillopsia, explaining the mechanism as the excitation of the vestibular system and proprioceptive signal to eye movement for gaze holding system.

Gaze-evoked nystagmus (GEN) is counted as the most frequent nystagmus and is mostly seen in chronic MS (45%), except the upbeat nystagmus (UN), which is present in the acute phase.\textsuperscript{[187]} Upbeat nystagmus is usually associated with bilateral internuclear ophthalmoplegia (INO).\textsuperscript{[176]} UN in the primary position is caused by the lesion in the caudal medullary or pontine tegmentum. Characteristic of this nystagmus is that it changes with head position and diminishes in a prone or supine position. Downbeat nystagmus (DBN) is caused by the vestibular nuclei disinhibition due to the floccular nuclei lesion, but this is not as common in MS as UN.\textsuperscript{[188]} Among all the nystagmus in MS, APN and DBN are most responsive to treatment.\textsuperscript{[189]} Aminopyridine in DBN, baclofen in APN, and memantine in UN are the most effective medications tried.\textsuperscript{[190]} Botulinum toxin has been tried in acquired nystagmus, but side effect like diplopia and ptosis make it less favorable.\textsuperscript{[190]} Horizontal gaze-evoked nystagmus is more commonly associated with NMOSD as compared to MS.\textsuperscript{[191]} Central positional nystagmus and opsoconulare are rarely reported in MS.\textsuperscript{[192]}

See-saw nystagmus consists of supraduction and incyclotorsion of one eye and infraduction and excyclotorsion of other eyes and it is caused by the para sellar, chiasmal, or midbrain lesion.\textsuperscript{[193]}

Besides these, torsional nystagmus, skew deviation, and ocular micro-tremor have been rarely reported in demyelinating lesions.\textsuperscript{[194–196]}

**Conclusion**

MDs are not frequent in MS, but not as rare as earlier perceived. Tremor is the most common MD reported in MS, but other MDs may also occur and may even be the presenting feature. Questions are often raised regarding the causal relation between MDs and demyelinating diseases, but certain clues like abrupt onset, temporal relation with the demyelinating lesion, and response to treatment are helpful in making the correct diagnosis. With the evolution of better imaging studies and better evaluating modalities, MDs are more easily recognized and can help in the early recognition of the demyelinating disease, prognostication, and better management of the quality of life of patients with MS. So, physicians should always keenly observe these movements.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci 2013;328:1-8. doi: 10.1016/j.jns.2013.02.007.
2. Candeias da Silva C, Bichuetti DB, Azevedo Silva SMC, Ferraz HB, Oliveira EML, Borges V. Movement disorders in multiple sclerosis and neuromyelitis optica: A clinical marker of neurological disability. Parkinsonism Relat Disord 2018;51:73-8.
3. Shneyder N, Harris MK, Minagar A. Movement disorders in patients with multiple sclerosis. Handb Clin Neurol 2011;100:307-14.
4. Abboud H, Yu XX, Knuel K, Fernandez HH, Cohen JA. Movement disorders in early MS and related diseases: A prospective observational study. Neurol Clin Pract 2019;9:24-31.
5. Makhoul K, Ahdrab R, Riachi N, Chalah MA, Ayache SS. Tremor in multiple sclerosis—an overview and future perspectives. Brain Sci 2020;10:722. doi: 10.3390/brainsci10100722.
6. Charcot JM. Histologie de la sclérose en plaques. Gazette Ho pitaux 1868;41:554, 557-8, 566.
7. Rinker J JR II, Salter AR, Walker H, Amara A, Meador W, Cutter GR. Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: A cross-sectional survey. BMJ Open 2015;5:e006714.
8. Alusi SH, Worthington J, Glickman S, Findley LJ, Bain PG. Evaluation of three different ways of assessing tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:756-60.
9. Pittoc SJ, McClelland RL, Mayr WT, Rodriguez M, Matsumoto JY, et al. Prevalence of tremor in multiple sclerosis and associated disability in the olmsted county population. Mov Disord 2004;19:1482-5.
10. Deuschl G. Movement disorders in multiple sclerosis and their treatment. Neurodegener Dis Manag 2016;6:31-5.
11. Weinschenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville I, Ebers GC. The natural history of multiple sclerosis: A geographically based study. 1. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
12. Yerdelen D, Karatas M, Goksel B, Yildirim T. A patient with multiple sclerosis presenting with Holmes’ tremor. Eur J Neurol 2008;15:e2-e3.
13. Koch M, Mostert J, Heersema D, De Keyser J. Tremor in multiple sclerosis. J Neurol 2007;254:133-45.
14. Feys P, Maes F, Nuttin B, Helsen W, Maftuit V, Nagels G, et al. Relationship between multiple sclerosis intention tremor severity and lesion load in brainstem. Neuroreport 2005;16:1379-82.
15. Boonstra F, Florescu G, Evans A, Steward C, Mitchell P, Desmond P, et al. Tremor in multiple sclerosis is associated with cerebello-thalamic pathology. J Neural Transm 2017;124:1509-14.
16. Nakamura R, Kamakura K, Tadano Y, Hosoda Y, Nagata N, Tsuchiya K, et al. MR imaging findings of tremors associated with lesions in cerebellar outflow tracts: Report of two cases. Mov Disord 1993;8:209-12.
17. Bain PG. The management of tremor. J Neurol Neurosurg Psychiatry 2002;72(Suppl 1):13-9.
18. Hitchcock E. Dentine lesions for involuntary movement. Proc Roy Soc Med 1973;66:33-5.
19. Quinter J, Inmisich I, Albrecht H, Föllmann W, Glassauer S, Straube A.
Influence of visual and proprioceptive afferences on upper limb ataxia in patients with multiple sclerosis. J Neurol Sci 1999;163:61-9.

20. Alusi SH, Aziz TZ, Glickman S, Jahanshahi M, Stein JF, Bain PG. Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: a prospective case-controlled study. Brain 2001;124:1576-89.

21. Benabid AL, Pollack P, Gao D. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neuropsychiatry 1996;8:203-14.

22. Alqwaifly M. Treatment responsive Holmes tremor: Case report and literature review. Int J Health Sci Qassim Univ 2016;10:558-62.

23. Ondo W, Hesham V, Lewitt PA, Pawha R, Shih L, Tarsy D, et al. Comparison of the fahn-tolosa-marlin clinical rating scale and the essential tremor rating assessment scale. Mov Disord Clin Pract 2018;5:60-5.

24. Liu X, Miall C, Aziz TZ, Palace JA, Haggard PN, Stein JF. Analysis of action tremor and impaired control of movement velocity in multiple sclerosis during visually guided wrist tracking tasks. Mov Disord 1997;12:992-9.

25. Meador W, Salter AR, Rinker JR II. Symptomatic management of multiple sclerosis-associated tremor among participants in the NARCOMS registry. Int J MS Care 2016;14:57-3.

26. Bain PG, Findley LJ, Atchison P, Behari M, Vidalhiet M, Gresty M, et al. Assessing the tremor severity. J Neurol Neurosurg Psychiatry 1993;56:868-73.

27. McCreary JK, Rogers JA, Forwell SJ. Upper limb intention tremor in multiple sclerosis an evidence-based review of assessment and treatment. Int J MS Care 2018;20:211-23.

28. Rinker J, Salter A, Cutter G. Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab. Mult Scler Relat Disord 2014;3:505-12.

29. Nourbakhsh B, Stüve O. Isoniazid in autoimmunity: A trigger for paroxysmal symptoms in multiple sclerosis. J Neurol 2014;261:259-63.

30. Solaro C, Sire AD, Ucelli MM, Mueller M, Bergamaschi R, Gasperini C, et al. Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: A multicenter double-blind, placebo-controlled, crossover study. Eur J Neurol 2020;27:2209-16.

31. Koppel BS, Brust JC, Fife T, Bronstein J, Youssouf S, Gronseth G, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the guideline development subcommittee of the American academy of neurology. Neurology 2014;82:1556-63.

32. Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord 2015;30:313-27.

33. Marrosu F, Maleci A, Cocco E, Puligheddu M, Barberini L, Marrosu MG. Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Multiple Sclerosis 2007;13:1200-2.

34. Marrosu F, Maleci A, Cocco E, Puligheddu M, Marrosu MG. Vagal nerve stimulation effects on cerebellar tremor in multiple sclerosis. Neurology 2005;65:490.

35. Hooper J, Whittle IR. Long‑term outcome after thalamotomy for multiple sclerosis‑associated tremor. J Neurol Neurosurg Psychiatry 2013;155:2359‑64.

36. Schreglmann SR, Krauss JK, Chang JW, Bhatia KP, Kägi G. Functional lesionsal neurosurgery for tremor: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2005;76:638-42.

37. Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, et al. Paroxysmal dyskinesia in multiple sclerosis: Clinical‑radiological features and treatment. Case report of seven patients”. Mult Scler 2000;6:321-7.

38. Meineret A, Garcia B, Frisman S, Lannuzel A, Mariani LL, Roze E. Treatable Hyperkinetic Movement Disorders Not to Be Missed. Front Neurol 2021;12:659805. doi: 10.3389/fneur.2021.659805. PMID: 34925500; PMCID: PMC8671871.

39. Pareés I. Clinical commentary on “Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis” and “Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical‑radiological features and treatment. Case report of seven patients”. Mult Scler 2017;23:1797-8.

40. Matthews WB. Paroxysmal symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 1975;38:617-23.

41. Baguma M, Ossmann M. Paroxysmal kinesigenic dyskinesia as the presenting and only manifestation of multiple sclerosis after eighteen months of follow-up. J Mov Disord 2017;10:96-8.

42. Dehailan AS. Paroxysmal dystonia as an initial manifestation of multiple sclerosis. Arch Neurol 1984;41:747-50.

43. Tibbles JA, Barnes SE. Paroxysmal dystonic choreoathetosis of mount and reback. Pediatrics 1980;65:149-51.

44. Waln O, Jankovic J. Paroxysmal movement disorders. Neurol Clin 2015;33:137-52.

45. Tranchant C, Bhatia KP, Marsden CD. Movement disorders in multiple sclerosis. Mov Disord 1995;10:418-23.

46. Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autosipied. Neurology 1967;17:680-90.

47. Berger JR, Shermata WA, Melamed E. Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Arch Neurol 1984;41:747-50.

48. Tibbles JA, Barnes SE. Paroxysmal dystonic choreoathetosis of mount and reback. Pediatrics 1980;65:149-51.

49. Waln O, Jankovic J. Paroxysmal movement disorders. Neurol Clin 2015;33:137-52.

50. Tranchant C, Bhatia KP, Marsden CD. Movement disorders in multiple sclerosis. Mov Disord 1995;10:418-23.

51. Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autosipied. Neurology 1967;17:680-90.

52. Berger JR, Shermata WA, Melamed E. Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Arch Neurol 1984;41:747-50.

53. Méneret A, Garcin B, Frisman S, Lannuzel A, Mariani LL, Roze E. Treatable Hyperkinetic Movement Disorders Not to Be Missed. Front Neurol 2021;12:659805. doi: 10.3389/fneur.2021.659805. PMID: 34925500; PMCID: PMC8671871.

54. Pareés I. Clinical commentary on “Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis” and “Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical‑radiological features and treatment. Case report of seven patients”. Mult Scler 2017;23:1797-8.

55. Matthews WB. Paroxysmal symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 1975;38:617-23.

56. Baguma M, Ossmann M. Paroxysmal kinesigenic dyskinesia as the presenting and only manifestation of multiple sclerosis after eighteen months of follow-up. J Mov Disord 2017;10:96-8.

57. Dehailan AS. Paroxysmal dystonia as an initial presentation of multiple sclerosis posing a diagnostic challenge. Neurosciences 2019;24:236-9.

58. Spissu A, Cannas A, Ferrigno P, Pelaghi AE, Spissu M. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord 1999;14:331-5.

59. Da Silva CC, Bichuetti DB, de Azevedo Silva BMC, Ferraz HB, Oliveira EML, Borges V. Movement disorders in multiple sclerosis and neuroymelittys optica: A clinical marker of neurologic disability. Parkinsonism Relat Disord 2018;51:73-8.

60. Guillain G, Malloret P. Sclerose in plaques avec tremblement ctrkbelleux, parkinsonien et hemiballismus. La forme hypothalamo ptdonculaire de la sckrose en plaques. Bull Soc Med Hop Paris 1930;46:18S.192.
65. Abboud H, Fernandez HH, Mealy MA, Levy M. Spinal Movement disorders in neuromyelitis optica: An under-recognized phenomenon. Mov. Disord. Clin. Pract 2016;3:596-602.

66. Unterberger I, Trinka E. Diagnosis and treatment of paroxysmal dyskinesias revisited. Ther Adv Neurol Disord 2008;1:4-11.

67. McGuire S, Chanchani S, Khurana DS. Paroxysmal dyskinesias. Semin Pediatr Neurol 2018;25:75-81.

68. Usmani N, Bedi G, Lam BL, Shermata WA. Association between paroxysmal tonic spasms and neuromyelitis optica. Arch Neurol 2012;69:121-4.

69. Li QY, Wang B, Yang J, Zhou L, Bao JZ, Wang L, et al. Painful tonic spasm in Chinese patients with neuromyelitis optica spectrum disorder: Prevalence, subtype, and features. Mult Scler Relat Disord 2020;45:1-7. doi: 10.1016/j.msard.2020.102408.

70. Joynt RJ, Green D. Tonic seizures as a manifestation of multiple sclerosis. Arch Neurol 1962;6:293-9.

71. Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord 2002;17:726-34.

72. Toyokura Y, Sakuta M, Nakanishi T. Painful tonic seizures in multiple sclerosis. Neurology (Minneap) 1976;26:18-9.

73. Maimone D, Reder AT, Finocchiaro F. Internal capsule plaque and tonic spasms in multiple sclerosis. Arch Neurol 1991;48:427-9.

74. Zenzola, A, Mari DM, Blasi DR, Carella A, Lambert P. Paroxysyma dystonia with thalamic lesion in multiple sclerosis. Neurol Sci 2001;22:391-4.

75. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in Neuromyelitis optica. Arch Neurol 2012;69:1026-31.

76. Chung EJ. Letter to the Editor: Tonic spasms in acute transverse myelitis. J Clin Neurosci 2009;16:165-6.

77. Wingerchuk DM, Barwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.

78. Watson CP, Chiu M. Painful tonic seizures in multiple sclerosis. Localization of a lesion. Can J Neurol Sci 1979;6:359-61.

79. Flanagan EP, Weinshenker BG, Krecke KN, Lennon V A, Lucchinetti CF, Oksenberg JR, Polman CH, et al. MRI correlates for neuromyelitis optica: A comparative study. Brain 2001;124:1987-96.

80. Zhang Bao J, Huang W, Zhou L, Wang L, Chang X, Lu C, et al. Etiological, clinical, and radiological features of longitudinally extensive myelopathy in Chinese patients. J Clin Neurosci 2009;16:32-6.

81. Zhang, Li QY, Wang B, Yang J, Zhou L, Bao JZ, Wang L, et al. Painful tonic spasm in Chinese patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2020;45:1-7. doi: 10.1016/j.msard.2020.102408.

82. Voiculescu V, Apostol BP, Alecu C. Treatment with acetazolamide of paroxysmal tonic spasms with topiramate in a patient with multiple sclerosis. J Neurosci Res 2000;60:1633-4.

83. Smith CR, Scheinberg L. Coincidence of myoclonus and multiple sclerosis. Adv Neurol 1990;51:357-62.

84. Bojan M, Brown P, Thompson PD, Miller DH. Propriospinal myoclonus in multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:1086-8.

85. Jankovic J, Pardo R. Segmental myoclonus clinical and pharmacologic study. Arch Neurol 1986;43:1025-31.

86. Adhikari S, Thuringer A, Maali L, Jassam Y. Opsoclonus myoclonus syndrome in a postpartum period. Mult Scler Relat Disord 2021;50:102862. doi: 10.1016/j.msard.2021.102862.

87. Foschi M, Rizzo G, Ligouri R, Avoni P, Mancinelli L, Lugaresi A, Rossetti M, et al. Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. Sleep Med 2019;56:90-7.

88. Kabukus N, Taskin E, Aydin M. Segmental myoclonus as the presenting symptom of an acute disseminated encephalomyelitis: A case report. J Neurol Sci 2006;245:104-8.

89. Smith CR, Scheinberg L. Coincidence of myoclonus and multiple sclerosis. Adv Neurol 1990;51:357-62.

90. Zappalá G, et al. Myelitis and facial myokimia as the first manifestation of multiple sclerosis]. Rev Neurol Paris 1990;146:518‑21.

91. Jankovic J, Pardo R. Segmental myoclonus clinical and pharmacologic study. Arch Neurol 1986;43:1025-31.

92. Foschi M, Rizzo G, Ligouri R, Avoni P, Mancinelli L, Lugaresi A, et al. Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. Sleep Med 2019;56:90-7.

93. Berger B, Rijntjes M, Stehlin L, Stich O. Corticosteroid-responsive torticollis as a presenting symptom of multiple sclerosis. J Neurol Sci 2013;320:262-8.

94. Har‑Gil M, Evrani M, Watemberg N. Torticollis as the only manifestation of acute disseminated encephalomyelitis. J Child Neuro 2010;25:1415-8.

95. Rosebush PI, Hildebrand AM, Furlong BG, Masurek MF. Catatonic syndrome in a general psychiatric inpatient population: Frequency, clinical, and facial myokimia as the first manifestation of multiple sclerosis. Adv Neurol 1986;31:289-7.

96. Foschi M, Rizzo G, Ligouri R, Avoni P, Mancinelli L, Lugaresi A, Rossetti M, et al. Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. Sleep Med 2019;56:90-7.

97. Kabukus N, Taskin E, Aydin M. Segmental myoclonus as the presenting symptom of an acute disseminated encephalomyelitis: A case report. J Neurol Sci 2006;245:104-8.

98. Smith CR, Scheinberg L. Coincidence of myoclonus and multiple sclerosis. Adv Neurol 1990;51:357-62.

99. Zappalá G, et al. Myelitis and facial myokimia as the first manifestation of multiple sclerosis]. Rev Neurol Paris 1990;146:518‑21.
Singh and Pandey: Movement Disorder in Demyelinating Disease

Petzold A. Diagnosing and quantifying a common deficit in multiple sclerosis: Inter- nuclear ophthalmoplegia. Neurology 1997;27:614-9.

165. Yousef A, Devereux M, Gourraud P-A, Jonzzon S, Sauleman L, Waubant E, et al. Subclinical saccadic eye movement dysfunction in pediatric multiple sclerosis. J Child Neurol 2019;34:38-43.

166. Bronstein AM, Rudge P, Gresty MA, Du Boulay G, Morris J. Abnormalities of horizontal gaze: Clinical, oculographic, and magnetic resonance imaging findings, II: Gaze palsy and internuclear ophthalmoplegia. J Neurol Neurosurg Psychiat 1990;53:200-7.

167. Robinson DA. Oculomotor control signals. In: Lennerstrand G, Bach Ritz P, editors. Basic Mechanisms of Ocular Motility and Their Clinical Implications. Toronto: Pergamon Press; 1975. p. 337-74.

168. Breza M, Smyri N, Koutsis G, Anagnostou E, Anagnostou E, et al. Ocular flutter as presenting manifestation of pediatric MOG antibody-associated demyelination: A case report. Mult Scler 2019;25:122-5.

169. Solingen LD, Baloh RW, Myers L, Ellison G. Subclinical eye movement disorders in patients with multiple sclerosis. Neurology 1977;27:614-9.

170. Costanzo D, Tedeschi G, Allocca A, Tranchino G, Quattrone A, Sasso E, et al. The contribution of saccadic eye movements analysis, visual and auditory evoked responses to the diagnosis of multiple sclerosis. Clin Neurol Neurosurg 1989;91:123-8.

171. Frohman EM, Frohman TC, Fleckenstein J, Racke MK, Hawker K, Kramer PD. Ocular contralpulsion in multiple sclerosis: Clinical features and pathophysiological mechanisms. J Neurol Neurosurg Psychiatry 2001;70:688-92.

172. Ventre J, Vighetto A, Bailly G, Prablanc C. Saccade metrics in multiple sclerosis: Versional velocity disconjugacy as the best clue? J Neurol Sci 1991;102:144-9.

173. Vliet AGMV, Lith GHMV. Nystagmography as a diagnostic tool in multiple sclerosis. Doc Ophthalmol 1979;46:339-44.

174. Grillani A, Renken RJ, Vrijling ACL, Heutink J, Cornelissen FW. Eye Movement evaluation in multiple sclerosis and Parkinson’s disease using a standardized oculomotor and neuro-ophtalmic disorder assessment (SONDA). Front Neurol 2020;11:1-15. doi: 10.3389/fneur.2020.00971

175. Kanhai KMS, Bijvank JAN, Wagenaar YL, Klaassen ES, Lim K, Berghaeanu SC, et al. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial CNS. Neurosci Ther 2019;25:697-703.

176. Lizarz, Clough M, Millist M, Kalincik T, White OB, Fielding J. Impairment of smooth pursuit as a marker of early multiple sclerosis. Front Neurol 2016;7:1-7. doi: 10.3389/fneur.2016.00206.

177. Mastaglia FL, Black JL, Collins DW. Quantitative studies of saccadic and pursuit eye movements in multiple sclerosis. Brain 1979;102:817-34.

178. Prasad S, Galetta SL. Eye movement abnormalities in multiple sclerosis. Neurol Clin 2010;28:641-55.

179. Caen LO, Izquierdo G, Marteau R, Lhemitte F, Castaigne P, Hauw JJ. Late onset multiple sclerosis. A clinical study of 16 pathologically proven cases. Acta Neurol Scand 2009;72:56-60.

180. Barton JJ, Cox TA. Acquired pendular nystagmus in multiple sclerosis: Clinical observations and the role of optic neuropathy. J Neurol Neurosurg Psychiatriy 1993;56:262-7.

181. Jasse L, Vukusic S, Dubief FD, Vartin C, Piras C, Bernard M, et al. Persistent visual impairment in multiple sclerosis: Prevalence, mechanisms and resulting disability. Mult Scler 2015;19:1618-26.

182. Das VE, Oruganti P, Kramer PD, Leigh RJ. Experimental tests of a neural-network model for ocular oscillations caused by disease of central myelin. Exp Brain Res 2000;133:189-97.

183. Gresty MA, Ell JJ, Findley LJ. Acquired pendular nystagmus: Its characteristics, localising value and pathophysiology. J Neurol Neurosurg Psychiatry 1982;45:431-9.

184. Todd L, King J, Darlington CL, Smith PF. Optokinetic reflex dysfunction in multiple sclerosis. Neuroreport 2001;12:1399-402.

185. Beh SC, Tehrani AS, Kheradmand A. Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis. Neurology 2014;82:1380-1.

186. Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: Natural history and management. Clin Ophthalmol 2010;4:1409-22.

187. Baloh RW, Spooner JW. Downbeat nystagmus: A type of central vestibular nystagmus. Neurology 1981;31:304-10.

188. Amezcuau, L, Morrow MJ, Jirawuthiworavong GV. Multiple sclerosis: Review of eye movement disorders and update of disease-modifying therapies. Curr Opin Ophthalmol 2015;26:534-9.

189. Carruthers J. The treatment of congenital nystagmus with Botox. J Pediatr Ophthalmol Strabismus 1995;32:306-8.

190. Lee SU, kim HY, Choi JH, Choi YJ, Kim JS. Comparison of ocular motor findings between neuronyelitis optica spectrum disorder and multiple sclerosis involving the brainstem and cerebellum. Cerebellum 2019;18:511-8.

191. Rosenhall U. Positional nystagmus. Acta Otolaryngol Suppl 1988;455:17-20.

192. Samkoff LM, Smith CR. See-saw nystagmus in a patient with clinically definite MS. Eur Neurol 1994;34:228-9.

193. Gresty MA, Findley LJ, Wade P. Mechanism of rotatory eye movements in opsoclonus. Br J Ophthalmol 1980;64:923-5.

194. Coakley D. Minute Eye Movemen and Brain Stem Function. 1 ed. Clinical Observations and the Role of Optic Neuropathy. J Neurol Neurosurg Psychiatry 1993;56:262-7.

195. Roberg BL, Bruce JM, Feaster HT, O'Bryan SR, Westervelt HJ, Bergheanu SC, et al. Ocular flutter as presenting manifestation of pediatric MOG antibody-associated demyelination: A case report. Mult Scler 2019;25:122-5.

196. Solingen LD, Baloh RW, Myers L, Ellison G. Subclinical eye movement disorders in patients with multiple sclerosis. Neurology 1977;27:614-9.

197. Costanzo D, Tedeschi G, Allocca A, Tranchino G, Quattrone A, Sasso E, et al. The contribution of saccadic eye movements analysis, visual and auditory evoked responses to the diagnosis of multiple sclerosis. Clin Neurol Neurosurg 1989;91:123-8.

198. Frohman EM, Frohman TC, Fleckenstein J, Racke MK, Hawker K, Kramer PD. Ocular contralpulsion in multiple sclerosis: Clinical features and pathophysiological mechanisms. J Neurol Neurosurg Psychiatry 2001;70:688-92.

199. Ventre J, Vighetto A, Bailly G, Prablanc C. Saccade metrics in multiple sclerosis: Versional velocity disconjugacy as the best clue? J Neurol Sci 1991;102:144-9.

200. Frohman EM, O’Suilleabhain P, Dewey RB Jr, Frohman TC, Kramer PD. A new measure of disconjugacy in INO: The first-pass amplitude. J Neurol Sci 2003;210:65-71.

201. Vliet AGMV, Lith GHMV. Nystagmography as a diagnostic tool in multiple sclerosis. Doc Ophthalmol 1979;46:339-44.

202. Grillani A, Renken RJ, Vrijling ACL, Heutink J, Cornelissen FW. Eye Movement evaluation in multiple sclerosis and Parkinson’s disease using a standardized oculomotor and neuro-ophtalmic disorder assessment (SONDA). Front Neurol 2020;11:1-15. doi: 10.3389/fneur.2020.00971

203. Kanhai KMS, Bijvank JAN, Wagenaar YL, Klaassen ES, Lim K, Berghaeanu SC, et al. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial CNS. Neurosci Ther 2019;25:697-703.

204. Lizarz, Clough M, Millist M, Kalincik T, White OB, Fielding J. Impairment of smooth pursuit as a marker of early multiple sclerosis. Front Neurol 2016;7:1-7. doi: 10.3389/fneur.2016.00206.

205. Mastaglia FL, Black JL, Collins DW. Quantitative studies of